Unveiling the Facts: Ozempic, GLP-1 Drugs, and Their Connection to Vision
Headlines about "Ozempic blindness" can be frightening, especially for the millions of people who rely on GLP-1 drugs like semaglutide (the active ingredient in Ozempic and Wegovy) to manage type 2 diabetes or for weight loss. While some studies have linked these popular medications to a potentially higher risk of eye problems, medical experts want to set the record straight.
The term "Ozempic blindness" isn't an official diagnosis; it's an informal phrase referring to a very small, but not zero, risk. Here's a look at what the current research says and what patients should know.
Are GLP-1 Drugs a Cause for Concern?
While studies have raised questions, experts say the current evidence doesn't support a cause for alarm. The overall risk of vision problems is extremely low. Dr. Sunir Garg, a spokesperson for the American Academy of Ophthalmology, notes that he has yet to see a patient with vision loss directly attributable to a GLP-1 medication.
Both Dr. Garg and Dr. Brian VanderBeek, an associate professor of ophthalmology at the University of Pennsylvania, emphasize that the benefits of these drugs—such as weight loss and improved blood sugar and blood pressure—far outweigh the minimal risks for most people.
The drug labels for Ozempic and Mounjaro list "changes in vision" as a possible side effect, and while lawsuits have been filed against the manufacturer, Novo Nordisk maintains that the risk of a serious eye condition called Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) is "very rare" and not an adverse drug reaction.
Potential Eye Conditions Linked to GLP-1s
Current research has reported links to three primary eye conditions, though a direct cause-and-effect relationship has not been established:
- Diabetic Retinopathy: For people with pre-existing diabetic retinopathy, a rapid drop in blood sugar from a GLP-1 drug can temporarily worsen the condition. However, studies are increasingly finding this is a less significant issue than once thought.
- Nonarteritic Anterior Ischemic Optic Neuropathy (NAION): Sometimes called a "stroke of the optic nerve," this condition can cause sudden, permanent vision loss. A recent study found an association between semaglutide and an increased risk of NAION, but the World Health Organization estimates this is a very rare side effect, affecting as few as 1 in 10,000 users.
- Macular Degeneration: A large 2025 study found a "substantially higher risk" of developing wet age-related macular degeneration in older adults with diabetes taking GLP-1 drugs. However, Dr. Garg points out that the risk only went from 1 in 1,000 to 2 in 1,000, meaning the overall risk remains incredibly small.
What to Watch For
It's not possible to prevent these side effects, but it is crucial to be aware of the symptoms. Dr. VanderBeek and Dr. Garg advise watching for any sustained changes in vision.
- Blurriness
- Distortion or "waviness" in your vision
- Trouble reading or seeing street signs
- Any missing parts in your field of vision
If you notice any of these symptoms, see an eye doctor right away. While there is no treatment for NAION, diabetic retinopathy and macular degeneration both have effective treatments.
Ultimately, medical professionals do not want patients to be so fearful of these medicines that they stop taking them and risk their overall health. For most patients, the benefits of GLP-1 drugs continue to far exceed the risks. If you are over 40, an annual eye exam is recommended, and you should always inform your eye doctor that you are taking a GLP-1 drug so they can be part of the conversation.
0 Comments